Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Skin Neoplasms 1Plasmablastic Lymphoma 1Oligodendroglioma 1Melanoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Glioma 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

Temozolomide 14Bevacizumab 11Erlotinib Hydrochloride 5Radiotherapy 4Carboplatin 4Magnetic Resonance Spectroscopy 3Irinotecan 3Immunoglobulin G 3Disulfides 3temsirolimus 2poly ICLC 2palbociclib 2etoposide phosphate 2antineoplaston AS 2-1 2antineoplaston A10 2Vincristine 2Sunitinib 2Sirolimus 2Everolimus 2Dasatinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1varlilumab 1vandetanib 1trebananib 1trametinib 1terameprocol 1tandutinib 1selinexor 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Oligodendroglioma × varlilumab × Clear all
NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

University of California, San Francisco

Phase 1 Terminated
14 enrolled 10 charts
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡